Valeant Pharmaceuticals International (VRX) announced Monday that it agreed to acquire Bausch & Lomb for $8.7 billion in cash.
The company also announced Tuesday that it received a Complete Response Letter from the FDA regarding its New Drug Application for efinaconazole for the treatment of onychomycosis.
Valeant Pharmaceuticals gapped open sharply higher Tuesday, but retreated during the first half of the morning, before settling into a range. Shares finished up by 7.33 at $91.80 on strong volume. The stock rose to its second consecutive new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.